02.05.26 -- Building Enterprise Resilience From QRM Signals

By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

Bispecific antibodies (bsAbs) offer transformative therapeutic potential through dual-target engagement, but their complex structure presents significant manufacturing challenges.

Collaborate with an experienced CMO that combines transparency, expertise, and a shared commitment to help advance complex biologics from preclinical research to clinical success.

With a growing interest in developing new and improved bioconjugate drugs, explore an “innovation through collaboration” approach that can facilitate access to next-generation conjugation technologies.

Examine how vaccine vial inspection can be boosted with automated visual inspection to improve accuracy, efficiency, and capacity to 20 million vials annually.

Developing robust, scalable microbial fermentation depends on optimizing growth and expression phases through efficient oxygen transfer, fine-tuning of nutrient delivery, and induction of protein expression.

RNA sequence and guide modifications, delivery platform design, and dose optimization all contribute to improved gene editing outcomes, which offer a clearer path toward scalable mRNA-based therapeutics.

Discover how a proprietary transposase technology works and why it can be beneficial for the development process for the expression of biologics.

CDMOs must have unique abilities to complete your project within your timeline. Gain insights as an industry expert reviews one of the most sought-after and fastest-growing CDMOs in the industry.

Review the pros and cons of soluble and insoluble processes, experiences with isolating, solubilizing, and properly re-folding, and strategies and innovation to improve insoluble processes.